CAPE TOWN, SA / ACCESSWIRE / November 2, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update on its Medspresso and Handcrafted Delights brands:
The Launch Announcement
The launch of Medspresso and Handcrafted Delights will be celebrated November 7th, 2020 at our partner, Caffeluxe‘s showroom, in Cape Town, South Africa. The event will include free tastings of the entire premium product range, consisting of CBD-infused African coffee, Rooibos tea, decadent Ivory Coast hot chocolate and delectable guilt-free cookies. There will also be interesting competitions with great hampers, vouchers and prizes up for grabs to start off the journey on a high note!
“We are excited to see the reactions and get most valuable feedback from our future customers. We are very confident they will absolutely love them and appreciate the care and quality with which they are produced. Nothing but the very best for our customers!” said Wuhan General Group CEO, Jeff Robinson.
The event will be open to all and specifically those interested in learning about the miraculous world of CBD. Customers will be able to treat themselves to 4 CBD-infused beverages and 10 mouthwatering CBD cookies like the Matcha White Chocolate Chip, Lavender and Fynbos Honey Shortbread and the Dark Ivory Coast Chocolate Macaron Cookie. RSVP to the event here. The entire line will be available for purchase here: Medspresso E-Commerce website.
“It has been quite the expedition in getting these 2 lines ready for launch with Covid-19 and all the supply chain issues. The team has put in so much hard work and I’m so very proud of all of the members,” added Wuhan General Group CMO, Dr. Anna Morera Leralta.
The combined launch of Medspresso and Handcrafted Delights is highly anticipated. It is a major milestone for Wuhan and the timing is perfect with the ranges being available just in time for the holiday season.
‘’We are thrilled to see these two very unique brands available for sale at our showroom and online. Inquiries about Medspresso have been very robust across Africa and internationally,” said Michael Sachar, Commercial Director of CaffeLuxe.
About Wuhan General Group, Inc./ M2Bio Sciences, Inc
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, its wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
For further information:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Wuhan General Group, Inc.
View source version on accesswire.com: